NAS:VTGN (USA)

VistaGen Therapeutics Inc

$ 0.76 -0.02 (-1.94%)
Volume: 81,681 Avg Vol (1m): 472,210
Market Cap $: 31.43 Mil Enterprise Value $: 25.21 Mil
P/E (TTM): 0.00 P/B: 14.07
Earnings Power Value 0.77
Net Current Asset Value 0.04
Tangible Book 0.05
Projected FCF -1.94
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 106.53
Cash-To-Debt ranked higher than
52.32% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
VTGN: 106.53
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 2, Max: 232.71
Current: 106.53
0
232.71
Debt-to-Equity 0.04
Debt-to-Equity ranked higher than
97.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
VTGN: 0.04
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -99999999.99, Med: -0.43, Max: 1
Current: 0.04
-99999999.99
1
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -38.61
DISTRESS
GREY
SAFE
Beneish M-Score -9.21
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 1.76%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -461.16
ROE ranked lower than
96.06% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
VTGN: -461.16
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -461.16, Med: -220, Max: -80
Current: -461.16
-461.16
-80
ROA % -228.61
ROA ranked lower than
94.74% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
VTGN: -228.61
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -7495.4, Med: -558.99, Max: -69.57
Current: -228.61
-7495.4
-69.57
ROC (Joel Greenblatt) % -7717.03
ROC (Joel Greenblatt) ranked lower than
80.50% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
VTGN: -7717.03
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -45308.29, Med: -5634.89, Max: -819.05
Current: -7717.03
-45308.29
-819.05
3-Year Total EBITDA Growth Rate -15.70
3-Year EBITDA Growth Rate ranked higher than
93.64% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
VTGN: 47.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -666, Med: -25.8, Max: 47.2
Current: 47.2
-666
47.2
3-Year EPS w/o NRI Growth Rate 52.70
3-Year EPS w/o NRI Growth Rate ranked higher than
91.35% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
VTGN: 52.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -4.6, Max: 52.7
Current: 52.7
0
52.7

» VTGN's 30-Y Financials

Financials (Next Earnings Date: 2019-06-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VTGN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:CLSN XSWX:ADXN XCNQ:MYM LSE:C4XD TSX:HBP NAS:CLSD NAS:ICCC ROCO:4171 ROCO:6610 NAS:BLPH ASX:IMU OTCPK:CNBX OSTO:MVIR B NAS:BVXV OTCPK:PMCB ROCO:6580 ROCO:4186 LSE:DEST ASX:NOX ASX:ACW
Traded in other countries
Address 343 Allerton Avenue, South San Francisco, San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants.

Ratios

Current vs industry vs history
PB Ratio 14.07
PB Ratio ranked lower than
51.14% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
VTGN: 14.07
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 7.64, Med: 19.35, Max: 32.61
Current: 14.07
7.64
32.61
EV-to-EBIT -1.11
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
VTGN: -1.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -18.6, Med: -1.2, Max: -0.3
Current: -1.11
-18.6
-0.3
EV-to-EBITDA -1.11
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
VTGN: -1.11
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -18.7, Med: -1.2, Max: -0.3
Current: -1.11
-18.7
-0.3
Current Ratio 3.63
Current Ratio ranked higher than
67.78% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
VTGN: 3.63
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.67, Max: 10.53
Current: 3.63
0.01
10.53
Quick Ratio 3.63
Quick Ratio ranked higher than
68.34% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
VTGN: 3.63
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.67, Max: 10.53
Current: 3.63
0.01
10.53

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -145.90
3-Year Share Buyback Rate ranked lower than
96.38% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
VTGN: -145.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -145.9, Med: -26.4, Max: -16.9
Current: -145.9
-145.9
-16.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.20
Price-to-Tangible-Book ranked higher than
56.94% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
VTGN: 15.2
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.36, Med: 9.79, Max: 28.41
Current: 15.2
2.36
28.41
Earnings Yield (Joel Greenblatt) % -90.75
Earnings Yield (Greenblatt) ranked lower than
89.92% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
VTGN: -90.75
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -327.4, Med: -80.3, Max: -5.4
Current: -90.75
-327.4
-5.4

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N